According to a study conducted on gastric cancer, ketamine has been shown to possess anti‐tumor properties by promoting apoptosis and modulating the PI3K/Akt/mTOR pathway.[63] The activation of NK cells by Esketamine was found to have an anti‐tumor immune effect in studies conducted on pancreatic cancer and lung adenocarcinoma.[64] In our previous study, we made a fascinating discovery regarding the potential anti‐tumor properties of Esketamine when combined with DDP. Here, AKT1 is linked to gastric cancer.